My watch list  

Evotec and Celgene expand iPSC collaboration to include additional cell lines


Evotec AG announced that the Company will receive a $ 6 m payment from Celgene following Celgene’s decision to expand the collaboration to include additional cell lines.

Evotec and Celgene initiated the collaboration in December 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases. Currently approved drugs only offer short-term management of the patients’ symptoms and there is a huge unmet medical need for therapeutic modalities that slow down or reverse disease progression. The collaboration pursues an innovative approach to the discovery and development of novel medicines by leveraging Evotec’s unique human induced pluripotent stem cell (“iPSC”) technology platform, which is one of the largest and most sophisticated platforms in the industry.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: “This achievement is the latest example of the performance of our scientists and reflects continuous investment to enhance and expand Evotec’s iPSC platform. We are confident that the extended portfolio provides additional opportunities for further research into disease-modifying treatments which will ultimately benefit patients suffering from neurodegenerative conditions.”

Facts, background information, dossiers
  • neurodegenerative diseases
More about Evotec
  • News

    Evotec and Sanofi to develop novel drug candidates from academic research

    Evotec AG announced that it has established an initiative with Sanofi through the launch of a newly created BRIDGE, called LAB031, designed to accelerate drug discovery across multiple therapeutic areas. The BRIDGE LAB031 collaboration enables Evotec to access resources to enter research co ... more

    Evotec and Celgene enter partnership in the field of targeted protein degradation

    Evotec AG announced that Evotec and Celgene Corporation have entered into a third long-term strategic drug discovery and development partnership in the field of targeted protein degradation. In this collaboration, Evotec and Celgene will leverage Evotec's Panomics platform in order to iden ... more

    Evotec and CHDI Foundation extend ongoing collaboration to fight Huntington's disease

    Evotec AG announced that CHDI Foundation, Inc. has extended its collaboration with Evotec through to 2023. Over this period, CHDI may fund up to 75 full-time scientists at Evotec. The collaboration was initiated in 2006 and has grown considerably over this period to fully utilise Evotec’s b ... more

  • Companies

    Evotec Neurosciences GmbH

    Evotec is a leader in the discovery and development of novel small molecule drugs. The Company has established a powerful platform that is applicable to targets across all therapeutic areas and has specific expertise in the area of Central Nervous System (CNS) related diseases where it is b ... more

    Evotec AG

    Evotec is a leading drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches. The Company operates worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target ... more

More about Celgene
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE